Qlaris Bio Inc has appointed Robert Warner board director as the company advances its lead programme, QLS‑111, through late-stage clinical trials for the treatment of glaucoma. Mr Warner brings global commercial leadership in ophthalmology. His experience spans corporate strategy, financing and company building. Mr Warner is on the boards of multiple biotechnology and medical device organisations. Previous executive roles include president, North America, for Alcon. Founded in 2019, Qlaris Bio’s lead development programme is designed to address a significant unmet need in glaucoma treatment by targeting episcleral venous pressure.
Qlaris Bio announced the appointment on 27 January 2026.
Copyright 2026 Evernow Publishing Ltd.